Several cancer indications were identified as risk factors for serious outcomes from PD‐1 inhibitor–induced nAEs: skin cancer (p = 0.029), lung cancer (p < 0.0001), kidneys and urinary tract cancer (p = 0.014), liver and gallbladder cancer (p = 0.036), and nervous system cancer (p < 0.0001). The gene discussed is PDCD1; the disease is lung cancer.